AXGN

Axogen

Fundamental data last updated:April 13, 2026

company profile

SECTOR

Healthcare

industry

Medical Devices

Exchange

Nasdaq

County of HQ

United Kingdom

Next Earnings Date

05/14/26

Business Summary

ARM monetizes semiconductor intellectual property by designing processor architectures and licensing them to chip manufacturers rather than fabricating chips itself. This asset-light model enables scalability, driving revenue through upfront licensing fees and recurring royalties tied to unit shipments. Because its designs become embedded in long product cycles, switching costs are meaningful once customers commit to a specific architecture. Cash generation is therefore tied to global semiconductor volume growth, allowing the firm to participate broadly across end markets without carrying heavy manufacturing capital expenditures.

VALUATION

P/E

-

Market Cap ($M USD)

$1,658

Forward P/E

42.1

PEG

27.2

PRICE TO SALES

6.5

PRICE TO BOOK

12.9

EV / EBITDA

3321.50

5-Year Average P/E

DIVIDEND

Yield

-

Annual Payout

-

Payout Ratio

-

Consecutive Years of Dividend Growth

0

5-Year Dividend Growth Rate

-

Financial Health & Profitability

Earnings Per Share

-$0.34

Next Year EPS Growth Estimate

$0.76

Next Year Revenue Growth Estimate

16.60%

Return on Equity (ROE)

-12.20%

Operating Margin

-3.50%

Debt-to-Equity

0.5

Piotroski F-Score

6

Altman Z-Score

10.2

Return on Invested Capital (ROIC)

-4.30%%

Current Ratio

5.1

Quick Ratio

Gainseekers Quantitative Analysis

Summary

At 200x earnings and 34x sales, the market is pricing ARM for near-perfection, yet the Forward P/E of 69.6 still implies investors are willing to pay a massive premium for future growth that has yet to translate into proportionate profitability. The balance sheet is undeniably fortress-like, with an Altman Z-Score of 41.8 and a Current Ratio of 5.4 signaling negligible financial distress risk. However, a 10.30% operating margin and 9.70% ROIC do not justify this magnitude of multiple expansion on a traditional GARP framework. This is not a distressed asset; it is a hyper-premium asset where execution must be flawless to validate the valuation.

AI Exposure / Tech Reliance

Operating in Semiconductors within the Technology sector, ARM sits at the architectural layer of modern computing infrastructure, making it inherently exposed to AI-driven silicon demand cycles. As AI workloads proliferate across cloud and edge devices, semiconductor IP platforms become embedded in long-duration innovation cycles. This positions the company structurally within the backbone of next-generation compute expansion.

The Bull Case

A GARP investor could justify a position based on capital efficiency and financial stability rather than headline valuation. A 20.70% Return on Equity combined with a Piotroski F-Score of 6 indicates operational stability and fundamentally sound financial conditions, not deterioration. The company operates with a manageable Debt/Equity ratio of 18.80% and a strong liquidity cushion via a 5.4 Current Ratio, reducing downside balance sheet risk. Even with a 10.30% operating margin, the 9.70% ROIC shows the business is generating returns above capital cost thresholds typical for mature semiconductor IP models, and the Altman Z-Score of 41.8 virtually eliminates bankruptcy risk—an attractive trait for institutional allocators seeking durable compounders rather than turnaround stories.

The Bear Case

The valuation is the obvious structural flaw: a 200 P/E and 34 Price/Sales ratio create zero margin of safety, particularly when Forward P/E remains elevated at 69.6 and PEG Forward is not even defined. Earnings visibility is questionable, with EPS at 140.3 while EPS Next Year is estimated at $0.75, creating a disconnect that undermines confidence in near-term earnings stability. Operating margin at 10.30% does not support premium software-like multiples, and the 0.1 TTM yield with no dividend per share offers no income floor. With no Short % of Float data provided and unclear consensus strength, investors are effectively paying extreme growth multiples without proportional profitability metrics to anchor downside risk.

Market Sentiment & Smart Money

Short Interest %

6.10%

Analyst Consensus

1.3

Average Analyst Price Target

$40.55

Institutional Ownership %

85.70%

1-Year Beta

0.8

Insider Buying % (6 Mo)

2.10%%

Distance to 52-Week High

88.80%%

Distance to 52-Week Low

346.80%%